Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.13 +0.46 (+1.05%)
Streaming Delayed Price Updated: 10:14 AM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
From Exelixis, Inc.
Via Business Wire
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.